Breast cancer deaths among women aged 20 to 49 dropped significantly between 2010 and 2020, with the sharpest improvements occurring after 2016. The findings were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, offering new insight into how treatment advances and healthcare access are saving lives—while also revealing areas where progress remains uneven.
Mortality Rates Down, Especially After 2016
Using data from the Surveillance, Epidemiology, and End Results (SEER) Program 17 registry, researchers analyzed 11,661 breast cancer deaths in U.S. women ages 20 to 49 between 2010 and 2020. The study focused on how breast cancer mortality trends vary by race and subtype—such as luminal A, luminal B, HER2-enriched, and triple-negative breast cancers.
The findings were encouraging. Incidence-based mortality declined dramatically—from 9.70 per 100,000 women in 2010 to 1.47 per 100,000 in 2020. The steepest year-over-year declines began after 2016, likely due to new treatments and improved access to care.
Luminal A breast cancer, often considered the least aggressive subtype, showed the most consistent decline. The biggest drop occurred in 2017, with a 32.88% annual percent change (APC). Triple-negative breast cancer, usually more aggressive, followed a similar trend, with a 32.82% decline in 2018.
Survival Varies by Age and Subtype
However, not all trends were expected. While luminal A usually has the best survival rate, that wasn’t the case for women under 40. Among women aged 20 to 39, 10-year survival for luminal A was 78.3%, lower than luminal B, which had an 84.2% survival rate.
“This was unexpected, as luminal A is generally the least aggressive subtype,” noted Dr. Toriola. “It may suggest a more complex biology in younger women that warrants further study.”
Racial Disparities Still Present
Despite overall improvements, racial disparities in breast cancer mortality persist. Non-Hispanic Black women had the highest mortality rates in both 2010 and 2020—16.56 and 3.41 deaths per 100,000, respectively. Non-Hispanic white women had the lowest, at 9.18 in 2010 and 1.16 in 2020.
Yearly improvements were seen across all groups:
- Non-Hispanic Black women: largest drop in 2016 (–24.15% APC)
- Non-Hispanic Asian/Pacific Islander women: 2013 (–18.46% APC)
- Hispanic women: 2017 (–30.15% APC)
- American Indian/Alaska Native women: 2018 (–47.97% APC)
The 10-year relative survival was also lowest for non-Hispanic Black women and highest for non-Hispanic white and Asian/Pacific Islander women.
Advancements in Treatment Making a Difference
Dr. Toriola attributes much of the progress to medical innovations that became widely used after 2015. These include the adoption of CDK4/6 inhibitors and better use of endocrine therapies for hormone receptor-positive, HER2-negative cancers like luminal A.
“Precision medicine and better screening access for women aged 40 to 49 have likely played key roles,” he said.
Calls for Further Action and Research
Despite the encouraging decline in mortality, the study highlights the need for continued research and policy improvements.
“We must continue to study the tumor biology in younger women and ensure equitable access to care,” Dr. Toriola urged. “Screening and high-quality treatment should be accessible to all women, regardless of age or race.”
He emphasized the need for broader population-based screening for women 40 to 49 and targeted screening for younger high-risk women.
Study Limitations
The study had some limitations, including a 10-year follow-up period and smaller data sets for some racial/ethnic groups. Still, it offers one of the most comprehensive recent looks at how breast cancer outcomes are evolving for younger women.
Practical Takeaways for Women Under 50
Get screened: Women aged 40–49 should follow updated breast cancer screening guidelines. Younger women at high risk (family history, genetic predisposition) should consider earlier or additional screenings.
Know your subtype: If diagnosed, understanding the breast cancer subtype (luminal A, B, HER2-enriched, or triple-negative) can guide treatment options.
Advocate for care: Access to high-quality, personalized treatment can significantly improve outcomes.
Stay informed: Research continues to evolve. Stay in contact with healthcare providers and consider second opinions if treatment paths are unclear.
Related topics:
